This review summarizes the current understanding of the inherited basis for aortic aneurysmal disease and clearly highlights the need to differentiate between thoracic and abdominal aortic manifestations.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Descending Thoracic Aorta
February 19, 2019
February 14, 2019
In the latest issue of JACC, the Stanford group led by Dr. Dake published a retrospective study to evaluate the effectiveness of thoracic endovascular aortic repair (TEVAR) compared to open surgical repair for descending aortic aneurysms.
February 13, 2019
In this paper, Dr Coselli and colleagues analyzed their experience with spinal cord deficit (SCD) after 1114 extent II open thoracoabdominal aortic aneurysm repairs performed from 1991-2017.
February 8, 2019
The European Journal of Vascular and Endovascular Surgery published The European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aortoiliac artery aneurysms.
February 6, 2019
On February 4, 2019, Cook Medical announced recent approval from the US Food and Drug Administration for its Zenith Dissection Endovascular System. The system consists of a proximal stent-graft component and a distal bare stent component. It provides a less invasive alternative to open surgery for repair of type B dissections.
February 1, 2019
In this retrospective cohort study, Dr Ehrlich and his colleagues reported excellent early and long-term results of thoracic endovascular aortic repair (TEVAR) for 55 high-risk patients with life-threatening acute complicated type B aortic dissection. The mean age of patients was 52 ± 13 years.
January 22, 2019
The medical therapies for thoracic aortic aneurysm comprise of β-adrenergic blocking agents and angiotensin II type I receptor.
January 3, 2019
On December 20, 2018, the US Food and Drug Administration (FDA) issued a new warning against the use of fluoroquinolones in patients with connective tissue disorders and those predisposed to aortic disease.
December 4, 2018
Essential reading, paying particular attention to the table in Section 7: the European experts recommend, again, that in Marfan and other systematic connective tissue diseases conventional techniques are still advantageous because the landing zones will eventually degenerate.
November 26, 2018
The authors compared the early and long-term survival in 9165 patients undergoing medical therapy (95%), open repair (2%), and thoracic endovascular aortic repair (TEVAR, 2.9%) for uncomplicated acute type B dissection. One- and 5-year survivals were 84% and 60% for medical therapy, 76% and 67% for open repair, and 85% and 76% for TEVAR (log-rank, P